A Phase 3 interventional study of Apremilast and Placebo in Palmoplantar Pustulosis, sponsored by Amgen. Completed at 40 sites in Japan. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-04-09.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.
Among the 44 studies testing apremilast in Psoriasis, this one is the 17th largest by enrollment, is one of 2 that started in 2022, is one of 18 in phase 3, and was the 35th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:
Syeda Sana Zaman · Sites in Pakistan
Ages 18–60 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
Amgen
Ages 18–60 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Zarmeen Khawar · Sites in Pakistan
Ages 18–65
By country, each count listing its studies:
apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 176 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 103 across the 44 interventional studies. Of the 34 that completed or were terminated, 26 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
61 studies in Psoriasis by Amgen: 1 open now, 1 under way, none of them phase 3. Of 60 finished, 35 (58%) have results posted.
Among the 61 studies in Psoriasis by Amgen, this one is the 32nd largest by enrollment of the 49 interventional ones that give a count, is the only one that started in 2022, is one of 32 in phase 3, and was the 57th registered.
Amgen’s Psoriasis studies by the year they started, since 2000.
1 of the studies testing apremilast in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07908641AmgenComparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation | 2027-01-10 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing apremilast in Psoriasis, from their registry updates:
Among Amgen’s 61 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the efficacy of apremilast (AMG 407) twice daily (BID) compared with placebo in participants with Palmoplantar Pustulosis (PPP).
Key Inclusion Criteria
Key Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apremilast will be administered to participants twice daily (BID)
Drug: Apremilast
Matching placebo will be administered to participants twice daily (BID) until week 16. After week 16, Apremilast will be administered to participants BID.
Drug: Apremilast · Drug: Placebo
Oral tablets
Also known as: Otezla, AMG 407
Oral tablets
Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score (PPPASI-50) at Week 16
A PPPASI 50 response is defined as a ≥ 50% reduction in PPPASI total score from baseline. The PPPASI is a system used for assessing and grading the severity (in terms of erythema, pustules/vesicle and desquamation/scale) and area of PPP lesions and their response to therapy. The PPPASI produces a numeric score that can range from 0 to 72, with a higher score indicating more severe disease. Participants who discontinued investigational product before week 16 due to lack of efficacy, adverse event, or use of protocol-prohibited medication (intercurrent events) were to be considered as treatment failures as the result of the intercurrent event and the PPPASI-50 values for visits on and after the intercurrent event were imputed as non-responders. The missing PPPASI-50 values due to the other reasons were imputed using the multiple imputation method.
Time frame: Baseline and Week 16
Change From Baseline in PPPASI Total Score at Week 16
The PPPASI is a system used for assessing and grading the severity (in terms of erythema, pustules/vesicle and desquamation/scale) and area of PPP lesions and their response to therapy. The PPPASI produces a numeric score that can range from 0 to 72, with a higher score indicating more severe disease. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of intercurrent event (IE) (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the mixed-effects model for repeated measures (MMRM) application.
Time frame: Baseline and Week 16
Change From Baseline in Palmoplantar Pustulosis Severity Index (PPSI) Total Score at Week 16
The PPSI is a system used for assessing and grading the severity of PPP lesions and their response to therapy. Evaluation of skin lesion site are assessed separately for erythema, pustules/vesicle and desquamation/scale, where each are rated on a scale of 0 to 4 and summed to produce a numeric total score than can range from 0 to 12, with a higher score indicating more severe disease. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application.
Time frame: Baseline and Week 16
Change From Baseline in Visual Analogue Scale (VAS) Assessment for PPP Symptoms (Pruritus) at Week 16
Participants assessed the degree of pruritus itching symptoms on palms and soles caused by PPP on a VAS. The VAS score ranged from 0 to 100. The left-hand boundary (0) on the VAS represents no itch and the right-hand boundary (100) represents itch as severe as can be imagined by the participant. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application.
Time frame: Baseline and Week 16
Change From Baseline in VAS Assessment for PPP Symptoms (Pain/Discomfort) at Week 16
Participants assessed the degree of pain/discomfort symptoms on palms and soles caused by PPP on a VAS. The VAS score ranged from 0 to 100. The left-hand boundary (0) on the VAS represents no pain/discomfort and the right-hand boundary (100) represents pain/discomfort as severe as can be imagined by the participant. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application.
Time frame: Baseline and Week 16
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16
The DLQI is a skin disease-specific Quality of Life (QoL) questionnaire comprised of 10 items assessing the participant's status over the previous week. The DLQI was used to assess 6 different aspects that may affect QoL: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The DLQI produces a numeric score ranging from 0 to 30, with a higher score indicating more severe disease. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application.
Time frame: Baseline and Week 16
Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
TEAEs were defined as any untoward medical occurrence in a participant irrespective of a causal relationship with the study treatment that began or worsened on or after the first dose of study treatment. A serious TEAE met at least 1 of the following criteria: * Resulted in death. * Was immediately life-threatening. * Required in-patient hospitalization or prolongation of existing hospitalization. * Resulted in persistent or significant disability/incapacity. * Was a congenital anomaly/birth defect. * Was any other medically important serious event. TEAEs of interest were defined as any of the following: * Depression. * Serious infection. * Risk of triggering suicide. * Serious diarrhea, nausea and vomiting. * Malignancies. * Vasculitis and Vasculopathy. * Serious Hypersensitivity. * Weight change (weight decrease). Clinically significant changes in body weight, vital signs and laboratory abnormalities were also recorded as TEAEs.
Time frame: Placebo-controlled period: Day 1 to Week 16; Apremilast exposure period : Apremilast Day 1 to a maximum of Week 52 (plus 4 weeks safety follow-up)
Participants with palmoplantar pustulosis (PPP) took part in the study at 40 centers in Japan between 08 March 2022 and 01 June 2024.
| Milestone | Placebo-controlled Period: Placebo | Placebo-controlled Period: Apremilast | Active Treatment Period: Apremilast |
|---|---|---|---|
| Started | 88 | 88 | 0 |
| Received apremilast or placebo during placebo-controlled period | 88 | 88 | 0 |
| Completed | 86 | 86 | 0 |
| Not completed | 2 | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 |
| Milestone | Placebo-controlled Period: Placebo | Placebo-controlled Period: Apremilast | Active Treatment Period: Apremilast |
|---|---|---|---|
| Started | 0 | 0 | 172 |
| Received apremilast during the active treatment period | 0 | 0 | 172 |
| Completed | 0 | 0 | 164 |
| Not completed | 0 | 0 | 8 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 4 |
A PPPASI 50 response is defined as a ≥ 50% reduction in PPPASI total score from baseline. The PPPASI is a system used for assessing and grading the severity (in terms of erythema, pustules/vesicle and desquamation/scale) and area of PPP lesions and their response to therapy. The PPPASI produces a numeric score that can range from 0 to 72, with a higher score indicating more severe disease. Participants who discontinued investigational product before week 16 due to lack of efficacy, adverse event, or use of protocol-prohibited medication (intercurrent events) were to be considered as treatment failures as the result of the intercurrent event and the PPPASI-50 values for visits on and after the intercurrent event were imputed as non-responders. The missing PPPASI-50 values due to the other reasons were imputed using the multiple imputation method.
| percentage of participants | Placebo-controlled Period: Placebo | Placebo-controlled Period: Apremilast |
|---|---|---|
| Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score (PPPASI-50) at Week 16 | 35.3 (25.3 to 45.4) | 67.8 (57.9 to 77.6) |
The PPPASI is a system used for assessing and grading the severity (in terms of erythema, pustules/vesicle and desquamation/scale) and area of PPP lesions and their response to therapy. The PPPASI produces a numeric score that can range from 0 to 72, with a higher score indicating more severe disease. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of intercurrent event (IE) (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the mixed-effects model for repeated measures (MMRM) application.
| score on a scale | Placebo-controlled Period: Placebo | Placebo-controlled Period: Apremilast |
|---|---|---|
| Change From Baseline in PPPASI Total Score at Week 16 | -5.98 ± 0.999 | -12.12 ± 1.002 |
The PPSI is a system used for assessing and grading the severity of PPP lesions and their response to therapy. Evaluation of skin lesion site are assessed separately for erythema, pustules/vesicle and desquamation/scale, where each are rated on a scale of 0 to 4 and summed to produce a numeric total score than can range from 0 to 12, with a higher score indicating more severe disease. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application.
| score on a scale | Placebo-controlled Period: Placebo | Placebo-controlled Period: Apremilast |
|---|---|---|
| Change From Baseline in Palmoplantar Pustulosis Severity Index (PPSI) Total Score at Week 16 | -1.9 ± 0.24 | -3.4 ± 0.24 |
Participants assessed the degree of pruritus itching symptoms on palms and soles caused by PPP on a VAS. The VAS score ranged from 0 to 100. The left-hand boundary (0) on the VAS represents no itch and the right-hand boundary (100) represents itch as severe as can be imagined by the participant. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application.
| score on a scale | Placebo-controlled Period: Placebo | Placebo-controlled Period: Apremilast |
|---|---|---|
| Change From Baseline in Visual Analogue Scale (VAS) Assessment for PPP Symptoms (Pruritus) at Week 16 | -9.9 ± 2.68 | -17.6 ± 2.67 |
Participants assessed the degree of pain/discomfort symptoms on palms and soles caused by PPP on a VAS. The VAS score ranged from 0 to 100. The left-hand boundary (0) on the VAS represents no pain/discomfort and the right-hand boundary (100) represents pain/discomfort as severe as can be imagined by the participant. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application.
| score on a scale | Placebo-controlled Period: Placebo | Placebo-controlled Period: Apremilast |
|---|---|---|
| Change From Baseline in VAS Assessment for PPP Symptoms (Pain/Discomfort) at Week 16 | -7.5 ± 2.97 | -18.3 ± 2.96 |
The DLQI is a skin disease-specific Quality of Life (QoL) questionnaire comprised of 10 items assessing the participant's status over the previous week. The DLQI was used to assess 6 different aspects that may affect QoL: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The DLQI produces a numeric score ranging from 0 to 30, with a higher score indicating more severe disease. A negative change from baseline indicates a reduction in disease severity. The continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application.
| score on a scale | Placebo-controlled Period: Placebo | Placebo-controlled Period: Apremilast |
|---|---|---|
| Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16 | -0.8 ± 0.37 | -2.3 ± 0.37 |
TEAEs were defined as any untoward medical occurrence in a participant irrespective of a causal relationship with the study treatment that began or worsened on or after the first dose of study treatment. A serious TEAE met at least 1 of the following criteria: * Resulted in death. * Was immediately life-threatening. * Required in-patient hospitalization or prolongation of existing hospitalization. * Resulted in persistent or significant disability/incapacity. * Was a congenital anomaly/birth defect. * Was any other medically important serious event. TEAEs of interest were defined as any of the following: * Depression. * Serious infection. * Risk of triggering suicide. * Serious diarrhea, nausea and vomiting. * Malignancies. * Vasculitis and Vasculopathy. * Serious Hypersensitivity. * Weight change (weight decrease). Clinically significant changes in body weight, vital signs and laboratory abnormalities were also recorded as TEAEs.
| Participants | Placebo-controlled Period: Placebo | Placebo-controlled Period: Apremilast | Apremilast Exposure Period: Apremilast |
|---|---|---|---|
| Any TEAEs | 43 | 63 | 148 |
| Serious TEAEs | 1 | 1 | 9 |
| TEAEs of Interest | 3 | 1 | 8 |
Collected over Placebo-controlled period: Day 1 to Week 16; Apremilast exposure period : Apremilast Day 1 to a maximum of Week 52 (plus 4 weeks safety follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo-controlled Period: Placebo | 0/88 (0%) | 1/88 (1.1%) | 25/88 (28.4%) |
| Placebo-controlled Period: Apremilast | 0/88 (0%) | 1/88 (1.1%) | 46/88 (52.3%) |
| Apremilast Exposure Period: Apremilast | 0/174 (0%) | 9/174 (5.2%) | 99/174 (56.9%) |
| Event | Placebo-controlled Period: Placebo | Placebo-controlled Period: Apremilast | Apremilast Exposure Period: Apremilast |
|---|---|---|---|
| CataractEye disorders | 0/88 | 0/88 | 2/174 |
| Acute myocardial infarctionCardiac disorders | 1/88 | 0/88 | 0/174 |
| Pseudoaneurysm infectionInfections and infestations | 1/88 | 0/88 | 0/174 |
| Cerebellar haemorrhageNervous system disorders | 0/88 | 1/88 | 1/174 |
| Duodenal perforationGastrointestinal disorders | 0/88 | 0/88 | 1/174 |
| CholelithiasisHepatobiliary disorders | 0/88 | 0/88 | 1/174 |
| PyelonephritisInfections and infestations | 0/88 | 0/88 | 1/174 |
| Pyelonephritis acuteInfections and infestations | 0/88 | 0/88 | 1/174 |
| Viral infectionInfections and infestations | 0/88 | 0/88 | 1/174 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/88 | 0/88 | 1/174 |
| Event | Placebo-controlled Period: Placebo | Placebo-controlled Period: Apremilast | Apremilast Exposure Period: Apremilast |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/88 | 17/88 | 31/174 |
| Faeces softGastrointestinal disorders | 1/88 | 15/88 | 22/174 |
| NasopharyngitisInfections and infestations | 8/88 | 4/88 | 28/174 |
| NauseaGastrointestinal disorders | 1/88 | 10/88 | 23/174 |
| HeadacheNervous system disorders | 2/88 | 10/88 | 19/174 |
| COVID-19Infections and infestations | 4/88 | 4/88 | 18/174 |
| Palmoplantar pustulosisSkin and subcutaneous tissue disorders | 5/88 | 4/88 | 12/174 |
| EczemaSkin and subcutaneous tissue disorders | 3/88 | 5/88 | 11/174 |
| Back painMusculoskeletal and connective tissue disorders | 5/88 | 0/88 | 5/174 |
Intent-to-treat Population: Included all randomized participants (i.e., participants who entered the placebo-controlled period).
| Age, Continuous(years) | Placebo-controlled Period: Placebo | Placebo-controlled Period: Apremilast | Total |
|---|---|---|---|
| Mean | 56.0 ± 11.35 | 57.0 ± 11.32 | 56.5 ± 11.32 |
| Sex: Female, Male(Participants) | Placebo-controlled Period: Placebo | Placebo-controlled Period: Apremilast | Total |
|---|---|---|---|
| Female | 72 | 69 | 141 |
| Male | 16 | 19 | 35 |
| Ethnicity (NIH/OMB)(Participants) | Placebo-controlled Period: Placebo | Placebo-controlled Period: Apremilast | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 88 | 88 | 176 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo-controlled Period: Placebo | Placebo-controlled Period: Apremilast | Total |
|---|---|---|---|
| Asian | 88 | 88 | 176 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Mar 2022 to primary completion in Aug 2023, 17 months.
Results were first posted in Apr 2025, 1 year 7 months after primary completion. A results delay was requested in Apr 2024.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 17 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast